Erleada in the EU for metastatic prostate cancer

[Darryl]

The European Commission granted marketing authorization for Erleada to treat patients with metastatic hormone-sensitive prostate cancer, also known as metastatic castration-sensitive prostate cancer, in combination with androgen deprivation therapy. Erleada is already approved in the EU for the treatment of men with non-metastatic castration-resistant prostate cancer.

[Magnus1964]

Thanks Darryl. Now we have give the FDA a kick in the butt to get them moving on this.

[Waoz in reply to Magnus1964]

FDA approved it September 2019. My husband had just started it, he is stage 4, neuroendocrine and adenocarcenoma, Mets head to toe, just started Erleada last Friday, on Lupron 21/2 years. Too soon to tell how it’s going.

[Magnus1964 in reply to Waoz]

Thanks, Erleada is approved for castrate sensitive Pca.

[Hirsch in reply to Waoz]

Do you know when it was approved?

[tallguy2]

It's about time the EU got on board.

Erleada (apalutamide) is already FDA approved in this situation (metastatic, hormone-sensitive PCa).

Today I started a Phase II trial using abiraterone and apalutamide for castration-resistant, metastatic PCa. I may be one of the last men joining this trial, which started in 2017.

Wish me luck.